Magazine article Drug Topics

New Product Newswire

Magazine article Drug Topics

New Product Newswire

Article excerpt

Rx

NEW DRUGS

Kenwood Therapeutics, Fairfield, N.J., (973) 882-2402, a division of Bradley Pharmaceuticals, has reported the introduction of Peranex HC Cream (hydrocortisone acetate 2%/lidocaine HCl 2%) on behalf of its Kenwood Therapeutics division. This is the first in a new line of anorectal anti-inflammatory and anesthetic products for the relief of itching and painful hemorrhoids, anal fissures, and other conditions of the anal area.

Cephalon Inc., Frazer, Pa., (610) 344-0200, has been granted FDA approval for Nuvigil (armodafinil) Tablets [C-IV], a single-isomer formulation of modafinil, the active ingredient in Provigli. Nuvigil is a non-amphetamine wake-promoting agent indicated to treat excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift-work disorders.

Stiefel Laboratories, Coral Gables, FIa., (888) 784-3335, has received PDA approval for Extina (ketoconazole) Foam 2% for the treatment of seborrheic dermatitis. Its VersaFoam delivery hastens absorption into the skin.

A.T.S. Pharmaceuticals, Los Angeles, (866) 367-8796, a division of Auriga Laboratories, is launching the Xyralid RC (lidocaine HCl 3%/hydrocortisone 1%) rectal cream kit for the treatment of hemorrhoids. The kit contains a sevenday supply of Xyralid Rectal Cream and a seven-day supply of Konsyl, a 100% psyllium laxative.

IMEW PELIVERV

Exelon Patch (rivastigmine transdermal system) has been approved for the treatment of Alzheimer's disease. The once-daily skin patch is approved to treat mild to moderate Alzheimer's disease and mild to moderate Parkinson's disease dementia with continuous delivery over 24 hours. This form of drug delivery is said to greatly reduce the gastrointestinal side effects of the drug. Exelon is available also as a capsule and in an oral solution.

Rapid-Acting Apidra (insulin glulisine [rDNA origin] injection), from Sanofi-Aventis, Bridgewater, N.J., (908) 243-6000, represents an additional treatment option for hospitalized diabetes patients with high blood sugar who may benefit from intravenous insulin therapy. Apidra was originally approved in 2004 for adult patients with Type 1 or Type 2 diabetes.

IUEW DOSAGE STRENGTHS

American Health Packaging, Columbus, Ohio, (800) 707-4621, has launched a number of new unit-dose items. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.